Akebia Therapeutics, Inc. AKBA
- Vafseo — Anemia Due to Chronic Kidney Disease Approved
- AKB-9090 — Acute Kidney Injury Phase 1
- AKB-9090 — Acute Respiratory Distress Syndrome Preclinical
- AKB-10108 — Retinopathy of Prematurity Preclinical
Home › Targets › HIF prolyl hydroxylase
HIF prolyl hydroxylase (1 companies · 4 programs)
Companies with an active program directed at HIF prolyl hydroxylase.